Production of Human Monoclonal IgE from Patients with Allergic Bronchopulmonary Mycosis
Sunday, March 6, 2016
South Exhibit Hall H (Convention Center)
Mark Wurth, MD PhD, Dennis J Horvath, PhD, Rebekah F Brown, MD, Yasmin W. Khan, MD, Ryszard Dworski, MD PhD, Scott A. Smith, MD, PhD
Rationale: Allergy to mold is associated with significant morbidity, including increased rates of hospitalization and ICU admission for asthmatics.  A subset of patients with asthma will go on to develop exuberant Th2 inflammation directed against mold colonizing their airway (Allergic Bronchopulmonary Mycosis).  Understanding the development of the IgE response to mold has been limited by the lack of human monoclonal IgE antibodies directed against mold.

Methods:  Patients within the Vanderbilt system with diagnosis of allergic bronchopulmonary mycosis were identified and recruited to the study. Peripheral blood mononuclear cells were isolated and placed under conditions to enhance B-cell growth in cell culture.  B-cell cultures were screened for IgE secretion by ELISA and fused with human derived myeloma partners using electrical cytofusion methods. Human hybridomas were identified by placing in selective media (hypoxanthine, aminopterin, and thymidine) and subsequently assaying for IgE secretion.

Results: We report the production of IgE secreting human hybridomas from patients with allergic bronchpulmonary mycosis. Additional characterization of these antibodies will be presented.

Conclusions:  Production of monoclonal IgE represents a novel tool to understand the evolution of the B-cell response in allergic patients.